Avadel Pharmaceuticals PLC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Avadel Pharmaceuticals reports significant revenue growth and profitability, driven by LUMRYZ sales, and announces its acquisition by Alkermes plc for $18.50 cash plus a $1.50 CVR per share.
Avadel Pharmaceuticals PLC reported significant revenue and profit growth in Q2 2025, driven by increasing patient uptake of its narcolepsy drug LUMRYZ, alongside key regulatory and legal victories.
Avadel Pharmaceuticals' Q1 2025 net product revenue surged to $52.5 million, a 93.2% increase year-over-year, primarily driven by the continued commercialization of LUMRYZ.
Avadel Pharmaceuticals saw a significant increase in revenue during the third quarter of 2024, primarily driven by sales of its narcolepsy drug, LUMRYZ.
Avadel Pharmaceuticals saw a significant increase in revenue in the second quarter of 2024, primarily driven by sales of its narcolepsy drug, LUMRYZ.
Avadel Pharmaceuticals reported a net product revenue of $27.2 million for the first quarter of 2024, primarily driven by sales of its narcolepsy drug, LUMRYZ.